Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders

Eratne, Dhamidhu ; Kang, Matthew ; Malpas, Charles ; Simpson-Yap, Steve ; Lewis, Courtney ; Dang, Christa ; Grewal, Jasleen ; Coe, Amy ; Dobson, Hannah and Keem, Michael , et al. (2024) In Australian and New Zealand Journal of Psychiatry 58(1). p.70-81
Abstract

Objective: Blood biomarkers of neuronal injury such as neurofilament light (NfL) show promise to improve diagnosis of neurodegenerative disorders and distinguish neurodegenerative from primary psychiatric disorders (PPD). This study investigated the diagnostic utility of plasma NfL to differentiate behavioural variant frontotemporal dementia (bvFTD, a neurodegenerative disorder commonly misdiagnosed initially as PPD), from PPD, and performance of large normative/reference data sets and models. Methods: Plasma NfL was analysed in major depressive disorder (MDD, n = 42), bipolar affective disorder (BPAD, n = 121), treatment-resistant schizophrenia (TRS, n = 82), bvFTD (n = 22), and compared to the reference cohort (Control Group 2, n =... (More)

Objective: Blood biomarkers of neuronal injury such as neurofilament light (NfL) show promise to improve diagnosis of neurodegenerative disorders and distinguish neurodegenerative from primary psychiatric disorders (PPD). This study investigated the diagnostic utility of plasma NfL to differentiate behavioural variant frontotemporal dementia (bvFTD, a neurodegenerative disorder commonly misdiagnosed initially as PPD), from PPD, and performance of large normative/reference data sets and models. Methods: Plasma NfL was analysed in major depressive disorder (MDD, n = 42), bipolar affective disorder (BPAD, n = 121), treatment-resistant schizophrenia (TRS, n = 82), bvFTD (n = 22), and compared to the reference cohort (Control Group 2, n = 1926, using GAMLSS modelling), and age-matched controls (Control Group 1, n = 96, using general linear models). Results: Large differences were seen between bvFTD (mean NfL 34.9 pg/mL) and all PPDs and controls (all < 11 pg/mL). NfL distinguished bvFTD from PPD with high accuracy, sensitivity (86%), and specificity (88%). GAMLSS models using reference Control Group 2 facilitated precision interpretation of individual levels, while performing equally to or outperforming models using local controls. Slightly higher NfL levels were found in BPAD, compared to controls and TRS. Conclusions: This study adds further evidence on the diagnostic utility of NfL to distinguish bvFTD from PPD of high clinical relevance to a bvFTD differential diagnosis, and includes the largest cohort of BPAD to date. Using large reference cohorts, GAMLSS modelling and the interactive Internet-based application we developed, may have important implications for future research and clinical translation. Studies are underway investigating utility of plasma NfL in diverse neurodegenerative and primary psychiatric conditions in real-world clinical settings.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Behavioural variant frontotemporal dementia, bipolar, bvFTD, depression, diagnosis, neurofilament, psychiatric disorders, psychiatry, schizophrenia
in
Australian and New Zealand Journal of Psychiatry
volume
58
issue
1
pages
70 - 81
publisher
Informa Healthcare
external identifiers
  • pmid:37477141
  • scopus:85165656768
ISSN
0004-8674
DOI
10.1177/00048674231187312
language
English
LU publication?
yes
additional info
Funding Information: A.J.W. was supported by a Trisno Family Fellowship, funded in part by an NHMRC CRE (1153607). C.P. was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1105825), an NHMRC L3 Investigator Grant (1196508). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376C, #ADSF-21-831381C, and #ADSF-21-831377C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors acknowledge the financial support of the CRC for Mental Health. The Cooperative Research Centre (CRC) programme is an Australian Government Initiative. The authors acknowledge the CRC Scientific Advisory Committee, in addition to the contributions of study participants, clinicians at recruitment services, staff at the Murdoch Children’s Research Institute, staff at the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Aging, and research staff at the Melbourne Neuropsychiatry Centre, including coordinators Merritt, A., Phassouliotis, C., and research assistants, Burnside, A., Cross, H., Gale, S., and Tahtalian, S. Participants for this study were sourced, in part, through the Australian Schizophrenia Research Bank (ASRB), which is supported by the National Health and Medical Research Council of Australia (Enabling Grant N. 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. We thank the Chief Investigators and ASRB Manager: Carr, V., Schall, U., Scott, R., Jablensky, A., Mowry, B., Michie, P., Catts, S., Henskens, F., Pantelis, C., Loughland, C. We acknowledge the help of Jason Bridge for ASRB database queries. The authors are grateful for assistance from Brett Trounson and Dr Christopher Fowler and the team at The Florey Oak St Biobank. Funding Information: KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Programme for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC). This study was also supported by MACH MRFF RART 2.2, NHMRC (1185180), and Psychiatry and Rehabilitation Division, Region Skåne, Sweden. The role of these funding sources was to support research study staff and biosample analyses. Publisher Copyright: © The Royal Australian and New Zealand College of Psychiatrists 2023.
id
414814e7-8b27-466b-8ad0-6ad9f8eaedcd
date added to LUP
2023-08-08 09:33:24
date last changed
2024-04-20 01:10:14
@article{414814e7-8b27-466b-8ad0-6ad9f8eaedcd,
  abstract     = {{<p>Objective: Blood biomarkers of neuronal injury such as neurofilament light (NfL) show promise to improve diagnosis of neurodegenerative disorders and distinguish neurodegenerative from primary psychiatric disorders (PPD). This study investigated the diagnostic utility of plasma NfL to differentiate behavioural variant frontotemporal dementia (bvFTD, a neurodegenerative disorder commonly misdiagnosed initially as PPD), from PPD, and performance of large normative/reference data sets and models. Methods: Plasma NfL was analysed in major depressive disorder (MDD, n = 42), bipolar affective disorder (BPAD, n = 121), treatment-resistant schizophrenia (TRS, n = 82), bvFTD (n = 22), and compared to the reference cohort (Control Group 2, n = 1926, using GAMLSS modelling), and age-matched controls (Control Group 1, n = 96, using general linear models). Results: Large differences were seen between bvFTD (mean NfL 34.9 pg/mL) and all PPDs and controls (all &lt; 11 pg/mL). NfL distinguished bvFTD from PPD with high accuracy, sensitivity (86%), and specificity (88%). GAMLSS models using reference Control Group 2 facilitated precision interpretation of individual levels, while performing equally to or outperforming models using local controls. Slightly higher NfL levels were found in BPAD, compared to controls and TRS. Conclusions: This study adds further evidence on the diagnostic utility of NfL to distinguish bvFTD from PPD of high clinical relevance to a bvFTD differential diagnosis, and includes the largest cohort of BPAD to date. Using large reference cohorts, GAMLSS modelling and the interactive Internet-based application we developed, may have important implications for future research and clinical translation. Studies are underway investigating utility of plasma NfL in diverse neurodegenerative and primary psychiatric conditions in real-world clinical settings.</p>}},
  author       = {{Eratne, Dhamidhu and Kang, Matthew and Malpas, Charles and Simpson-Yap, Steve and Lewis, Courtney and Dang, Christa and Grewal, Jasleen and Coe, Amy and Dobson, Hannah and Keem, Michael and Chiu, Wei Hsuan and Kalincik, Tomas and Ooi, Suyi and Darby, David and Brodtmann, Amy and Hansson, Oskar and Janelidze, Shorena and Blennow, Kaj and Zetterberg, Henrik and Walker, Adam and Dean, Olivia and Berk, Michael and Wannan, Cassandra and Pantelis, Christos and Loi, Samantha M. and Walterfang, Mark and Berkovic, Samuel F. and Santillo, Alexander F. and Velakoulis, Dennis}},
  issn         = {{0004-8674}},
  keywords     = {{Behavioural variant frontotemporal dementia; bipolar; bvFTD; depression; diagnosis; neurofilament; psychiatric disorders; psychiatry; schizophrenia}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{70--81}},
  publisher    = {{Informa Healthcare}},
  series       = {{Australian and New Zealand Journal of Psychiatry}},
  title        = {{Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders}},
  url          = {{http://dx.doi.org/10.1177/00048674231187312}},
  doi          = {{10.1177/00048674231187312}},
  volume       = {{58}},
  year         = {{2024}},
}